{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T05:11:15Z","timestamp":1777093875475,"version":"3.51.4"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To determine the association between gene-expression profiling (GEP), next-generation sequencing (NGS), preferentially expressed antigen in melanoma (PRAME) features, and metastatic risk in patients with uveal melanoma (UM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective analysis of patients with UM treated by brachytherapy or enucleation by a single ocular oncologist was conducted from November 2020 and July 2022. Clinicopathologic features, patient outcomes, GEP classification, NGS, and PRAME results were recorded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Comprehensive GEP, PRAME, and NGS testing was performed on 135 UMs. The presence of eukaryotic translation initiation factor 1A, X-chromosomal and splicing factor 3B subunit 1 mutations was significantly associated with GEP class 1A and GEP class 1B, respectively. The presence of BRCA- associated protein-1 mutation was significantly associated with GEP class 2. The average largest basal diameter for tumors with eukaryotic translation initiation factor 1A, X-chromosomal mutations was significantly smaller than those with splicing factor 3B subunit 1 mutations and BRCA1-associated protein-1 mutations. Class 2 tumors metastasized sooner than GEP class 1 tumors. Tumors with splicing factor 3B subunit 1 and\/or BRCA1-associated protein-1 mutations metastasized sooner compared with tumors that had either no driver mutation or no mutations at all. Tumors with splicing factor 3B subunit 1 did not have a significantly different time to metastasis compared with tumors with BRCA1-associated protein-1 (<jats:italic toggle=\"yes\">P<\/jats:italic> value = 0.97). Forty tumors (30%) were PRAME positive, and the remaining 95 tumors (70%) were PRAME negative. Tumors with PRAME-positive status did not have a significantly different time to metastasis compared with tumors without PRAME-positive status (<jats:italic toggle=\"yes\">P<\/jats:italic> value = 0.11).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>GEP, NGS, and PRAME expression analysis help determine different levels of metastatic risk in UM. Although other prognostic tests exist, the following study reports on the use of NGS for metastatic prognostication in UM. However, limitations of NGS exist, especially with small lesions that are technically difficult to biopsy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004153","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:12:18Z","timestamp":1724371938000},"page":"1580-1589","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["COMPREHENSIVE MOLECULAR PROFILING OF UVEAL MELANOMA EVALUATED WITH GENE EXPRESSION PROFILING, PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA EXPRESSION, AND NEXT-GENERATION SEQUENCING"],"prefix":"10.1097","volume":"44","author":[{"given":"Amer F.","family":"Alsoudi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry C.","family":"Skrehot","sequence":"additional","affiliation":[{"name":"School of Medicine, Baylor College of Medicine, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Ch\u00e9vez-Barrios","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, Texas;"},{"name":"Department of Pathology and Genomic Medicine, Weill Cornell Medicine, Houston Methodist Hospital, Houston, Texas;"},{"name":"Blanton Eye Institute, Weill Cornell Medicine, Houston Methodist Hospital, Houston, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukul","family":"Divatia","sequence":"additional","affiliation":[{"name":"Department of Pathology and Genomic Medicine, Weill Cornell Medicine, Houston Methodist Hospital, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"De La Garza","sequence":"additional","affiliation":[{"name":"Department of Pathology and Genomic Medicine, Weill Cornell Medicine, Houston Methodist Hospital, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Bretana","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy C.","family":"Schefler","sequence":"additional","affiliation":[{"name":"Blanton Eye Institute, Weill Cornell Medicine, Houston Methodist Hospital, Houston, Texas; and"},{"name":"Retina Consultants of Texas, Houston, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"51","DOI":"10.12703\/r\/10-51","article-title":"Recent advancements in the management of retinoblastoma and uveal melanoma","volume":"10","author":"Schefler","year":"2021","journal-title":"Fac Rev"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13244-021-01000-x","article-title":"Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging\u2014part I: MR imaging with pathologic correlation and technical considerations","volume":"12","author":"Foti","year":"2021","journal-title":"Insights Imaging"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye (Lond)"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-10-2076","article-title":"Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification","volume":"16","author":"Damato","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R9-20250605","first-page":"6541","article-title":"Clinical, histopathological and cytogenetic prognosticators in uveal melanoma\u2014a comprehensive review","volume":"37","author":"Berus","year":"2017","journal-title":"Anticancer Res"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.exer.2012.04.010","article-title":"Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival","volume":"100","author":"Abdel-Rahman","year":"2012","journal-title":"Exp Eye Res"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/modpathol.2017.187","article-title":"Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma","volume":"31","author":"Smit","year":"2018","journal-title":"Mod Pathol"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/aos.15210","article-title":"A prognostic classification system for uveal melanoma based on a combination of patient age and sex, the American Joint Committee on Cancer and the Cancer Genome Atlas models","volume":"101","author":"Gill","year":"2023","journal-title":"Acta Ophthalmol"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.ophtha.2017.04.003","article-title":"Personalized prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8-year period: the 2017 Harry S. Gradle Lecture","volume":"124","author":"Shields","year":"2017","journal-title":"Ophthalmology"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ajo.2018.07.045","article-title":"Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma","volume":"195","author":"Cai","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat Genet"},{"key":"R19-20250605","first-page":"555","article-title":"PRAME induces genomic instability in uveal melanoma","volume":"43","author":"Harbour","year":"2024","journal-title":"Res Sq"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"59209","DOI":"10.18632\/oncotarget.10962","article-title":"Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in class 1 and class 2 uveal melanomas","volume":"7","author":"Field","year":"2016","journal-title":"Oncotarget"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3390\/cancers12041039","article-title":"Targeted next-generation sequencing of 117 routine clinical samples provides further insights into the molecular landscape of uveal melanoma","volume":"12","author":"Thornton","year":"2020","journal-title":"Cancers"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaophthalmol.2018.0561","article-title":"Yield, techniques, and complications of transvitreal and transscleral biopsies in small uveal melanoma","volume":"136","author":"Kim","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"MMT37","DOI":"10.2217\/mmt-2020-0001","article-title":"Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling","volume":"7","author":"Schefler","year":"2020","journal-title":"Melanoma Manag"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IIO.0000000000000160","article-title":"Micrometastatic dormancy in uveal melanoma: a comprehensive review of the evidence, mechanisms, and implications for future adjuvant therapies","volume":"57","author":"Nichols","year":"2017","journal-title":"Int Ophthalmol Clin"},{"key":"R26-20250605","first-page":"1868","article-title":"Risk-stratified systemic surveillance in uveal melanoma","volume":"103","author":"Davanzo","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"5325762","DOI":"10.1155\/2016\/5325762","article-title":"Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study","volume":"2016","author":"Plasseraud","year":"2016","journal-title":"J Oncol"},{"key":"R28-20250605","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2147\/OPTH.S70839","article-title":"Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses","volume":"8","author":"Aaberg","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R29-20250605","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/0301-4738.154367","article-title":"Uveal melanoma: estimating prognosis","volume":"63","author":"Kaliki","year":"2015","journal-title":"Indian J Ophthalmol"},{"key":"R30-20250605","first-page":"2578","article-title":"Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities","volume":"63","author":"Tschentscher","year":"2003","journal-title":"Cancer Res"},{"key":"R31-20250605","doi-asserted-by":"crossref","first-page":"100800","DOI":"10.1016\/j.preteyeres.2019.100800","article-title":"Uveal melanoma: towards a molecular understanding","volume":"75","author":"Smit","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"R32-20250605","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000502550","article-title":"BAP1 immunoreactivity correlates with gene expression class in uveal melanoma","volume":"6","author":"See","year":"2020","journal-title":"Ocul Oncol Pathol"},{"key":"R33-20250605","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/tvst.8.2.18","article-title":"Next-generation sequencing of uveal melanoma for detection of genetic alterations predicting metastasis","volume":"8","author":"Afshar","year":"2019","journal-title":"Transl Vis Sci Technol"},{"key":"R34-20250605","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/cncy.22264","article-title":"The diagnostic utility of next-generation sequencing on FNA biopsies of melanocytic uveal lesions","volume":"128","author":"Han","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"R35-20250605","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/eye.2009.235","article-title":"A reappraisal of the significance of largest basal diameter of posterior uveal melanoma","volume":"23","author":"Damato","year":"2009","journal-title":"Eye (Lond)"},{"key":"R36-20250605","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archopht.1992.01080140101036","article-title":"A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988","volume":"110","author":"Diener-West","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R37-20250605","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzyigitoglu","year":"2016","journal-title":"Ophthalmology"},{"key":"R38-20250605","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaophthalmol.2016.0903","article-title":"Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes","volume":"134","author":"Decatur","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R39-20250605","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1186\/s12885-018-5190-z","article-title":"Detection of mutations in SF3B1, EIF1AX and GNAQ in primary orbital melanoma by candidate gene analysis","volume":"18","author":"Rose","year":"2018","journal-title":"BMC Cancer"},{"key":"R40-20250605","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"R41-20250605","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ophtha.2017.07.018","article-title":"Uveal melanoma nuclear BRCA1-associated protein-1 immunoreactivity is an indicator of metastasis","volume":"125","author":"Szalai","year":"2018","journal-title":"Ophthalmology"},{"key":"R42-20250605","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/1471-2407-13-371","article-title":"BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma","volume":"13","author":"Matatall","year":"2013","journal-title":"BMC Cancer"},{"key":"R43-20250605","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1136\/bjophthalmol-2014-305047","article-title":"Prognostic parameters in uveal melanoma and their association with BAP1 expression","volume":"98","author":"van Essen","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R44-20250605","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ajo.2020.08.014","article-title":"Instrument gauge and type in uveal melanoma fine needle biopsy: implications for diagnostic yield and molecular prognostication","volume":"221","author":"Klofas","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R45-20250605","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2353\/jmoldx.2010.090220","article-title":"An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma","volume":"12","author":"Onken","year":"2010","journal-title":"J Mol Diagn"},{"key":"R46-20250605","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cancers11081075","article-title":"Uveal melanoma biopsy: a review","volume":"11","author":"Frizziero","year":"2019","journal-title":"Cancers"},{"key":"R47-20250605","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ajo.2018.08.045","article-title":"Are risk factors for growth of choroidal nevi associated with malignant transformation? Assessment with a validated genomic biomarker","volume":"197","author":"Harbour","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R48-20250605","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000517203","article-title":"Small choroidal melanoma: correlation of growth rate with pathology","volume":"7","author":"Raval","year":"2021","journal-title":"Ocul Oncol Pathol"},{"key":"R49-20250605","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaophthalmol.2015.1790","article-title":"Variable results for uveal melanoma-specific gene expression profile prognostic test in choroidal metastasis","volume":"133","author":"Klufas","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R50-20250605","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000526770","article-title":"Comparative metastatic rates in GEP class 1A versus 1B posterior uveal melanoma: results contrary to expectations","volume":"8","author":"Augsburger","year":"2023","journal-title":"Ocul Oncol Pathol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:04:36Z","timestamp":1749143076000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004153","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}